Rachel Lennon

Rachel Lennon

Auto-generated profile, based on publicly available information

Rachel Lennon

Manchester Cell-Matrix Centre, The University of Manchester, Manchester, United Kingdom

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Cell Metabolism
Verified
Journal Article
Closed access
GWGavin Welsh
Gavin Welsh
LHLorna J. Hale
Lorna J. Hale
VEVera Eremina
Vera Eremina
MJMarie Jeansson
Marie Jeansson
YMYoshiro Maezawa
Yoshiro Maezawa
RCRichard Coward
Richard Coward

1 November 2005 in Diabetes
Verified
Journal Article
Closed access
PDF file
RCRichard Coward
Richard Coward
GWGavin Welsh
Gavin Welsh
JYJing Yang
Jing Yang
CTCandida Tasman
Candida Tasman
RLRachel Lennon
Rachel Lennon
MSMoin A. Saleem
Moin A. Saleem
Microalbuminuria is significant both as the earliest stage of diabetic nephropathy and as an independent cardiovascular risk factor in nondiabetic subjects, in whom it is associated with insulin resistance. The link between disorders of cellular insulin metabolism and albuminuria has been elusive. Here, we report using novel conditionally immortalized human podocytes in vitro and human glomeruli ex vivo that the podocyte, the principal cell responsible for prevention of urinary protein loss, is insulin responsive and able to approximately double its glucose uptake within 15 min of insulin stimulation. Conditionally immortalized human glomerular endothelial cells do not respond to insulin, suggesting that insulin has a specific effect on the podocyte in the glomerular filtration barrier. The insulin response of the podocyte occurs via the facilitative glucose transporters GLUT1 and GLUT4, and this process is dependent on the filamentous actin cytoskeleton. Insulin responsiveness in this key structural component of the glomerular filtration barrier may have central relevance for understanding of diabetic nephropathy and for the association of albuminuria with states of insulin resistance.

24 August 2020 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
RNRichard W. Naylor
Richard W. Naylor
MMMychel R. P. T. Morais
Mychel R. P. T. Morais
RLRachel Lennon
Rachel Lennon

4 December 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
LHLorna J. Hale
Lorna J. Hale
SHSara E. Howden
Sara E. Howden
BPBelinda Phipson
Belinda Phipson
ALAndrew Lonsdale
Andrew Lonsdale
PEPei X. Er
Pei X. Er
MLMelissa H. Little
Melissa H. Little
The podocytes within the glomeruli of the kidney maintain the filtration barrier by forming interdigitating foot processes with intervening slit diaphragms, disruption in which results in proteinuria. Studies into human podocytopathies to date have employed primary or immortalised podocyte cell lines cultured in 2D. Here we compare 3D human glomeruli sieved from induced pluripotent stem cell-derived kidney organoids with conditionally immortalised human podocyte cell lines, revealing improved podocyte-specific gene expression, maintenance in vitro of polarised protein localisation and an improved glomerular basement membrane matrisome compared to 2D cultures. Organoid-derived glomeruli retain marker expression in culture for 96 h, proving amenable to toxicity screening. In addition, 3D organoid glomeruli from a congenital nephrotic syndrome patient with compound heterozygous NPHS1 mutations reveal reduced protein levels of both NEPHRIN and PODOCIN. Hence, human iPSC-derived organoid glomeruli represent an accessible approach to the in vitro modelling of human podocytopathies and screening for podocyte toxicity.

20 May 2022 in Science Advances
Verified
Journal Article
Open access
RJRanjay Jayadev
Ranjay Jayadev
MMMychel R. P. T. Morais
Mychel R. P. T. Morais
JEJamie Ellingford
Jamie Ellingford
SSSandhya Srinivasan
Sandhya Srinivasan
RNRichard W. Naylor
Richard W. Naylor
RLRachel Lennon
Rachel Lennon
Basement membranes (BMs) are ubiquitous extracellular matrices whose composition remains elusive, limiting our understanding of BM regulation and function. By developing a bioinformatic and in vivo discovery pipeline, we define a network of 222 human proteins and their animal orthologs localized to BMs. Network analysis and screening in C. elegans and zebrafish uncovered BM regulators, including ADAMTS, ROBO, and TGFβ. More than 100 BM network genes associate with human phenotypes, and by screening 63,039 genomes from families with rare disorders, we found loss-of-function variants in LAMA5 , MPZL2 , and MATN2 and show that they regulate BM composition and function. This cross-disciplinary study establishes the immense complexity of BMs and their impact on in human health.

1 February 2015 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
MFMaryline Fresquet
Maryline Fresquet
TJThomas A. Jowitt
Thomas A. Jowitt
JGJennet Gummadova
Jennet Gummadova
RCRichard Collins
Richard Collins
RORonan O’cualain
Ronan O’cualain
PBPaul E. Brenchley
Paul E. Brenchley
Phospholipase A2 receptor 1 (PLA2R) is a target autoantigen in 70% of patients with idiopathic membranous nephropathy. We describe the location of a major epitope in the N-terminal cysteine-rich ricin domain of PLA2R that is recognized by 90% of human anti-PLA2R autoantibodies. The epitope was sensitive to reduction and SDS denaturation in the isolated ricin domain and the larger fragment containing the ricin, fibronectin type II, first and second C-type lectin domains (CTLD). However, in nondenaturing conditions the epitope was protected against reduction in larger fragments, including the full-length extracellular region of PLA2R. To determine the composition of the epitope, we isolated immunoreactive tryptic fragments by Western blotting and analyzed them by mass spectrometry. The identified peptides were tested as inhibitors of autoantibody binding to PLA2R by surface plasmon resonance. Two peptides from the ricin domain showed strong inhibition, with a longer sequence covering both peptides (31-mer) producing 85% inhibition of autoantibody binding to PLA2R. Anti-PLA2R antibody directly bound this 31-mer peptide under nondenaturing conditions and binding was sensitive to reduction. Analysis of PLA2R and the PLA2R-anti-PLA2R complex using electron microscopy and homology-based representations allowed us to generate a structural model of this major epitope and its antibody binding site, which is independent of pH-induced conformational change in PLA2R. Identification of this major PLA2R epitope will enable further therapeutic advances for patients with idiopathic membranous nephropathy, including antibody inhibition therapy and immunoadsorption of circulating autoantibodies.